CR8615A - Polimorfo cristalino de un acetato de bazedoxifeno - Google Patents

Polimorfo cristalino de un acetato de bazedoxifeno

Info

Publication number
CR8615A
CR8615A CR8615A CR8615A CR8615A CR 8615 A CR8615 A CR 8615A CR 8615 A CR8615 A CR 8615A CR 8615 A CR8615 A CR 8615A CR 8615 A CR8615 A CR 8615A
Authority
CR
Costa Rica
Prior art keywords
crystal polymorph
bazedoxifen acetate
acetate
bazedoxifen
polymorph
Prior art date
Application number
CR8615A
Other languages
English (en)
Inventor
Demerson Christopher
Iera Silvio
A Ali Kadum
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8615A publication Critical patent/CR8615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion esta dirigida a un polimorfo crsitalino de acetato de bazedoxifeno, composiciones que contienen el mismo, preparaciones del mismo y usos del mismo.
CR8615A 2004-04-07 2006-09-12 Polimorfo cristalino de un acetato de bazedoxifeno CR8615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058204P 2004-04-07 2004-04-07
US66017805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
CR8615A true CR8615A (es) 2007-06-06

Family

ID=34966308

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8615A CR8615A (es) 2004-04-07 2006-09-12 Polimorfo cristalino de un acetato de bazedoxifeno

Country Status (18)

Country Link
US (1) US7683051B2 (es)
EP (1) EP1732890A1 (es)
JP (2) JP2007532560A (es)
KR (1) KR20060135866A (es)
AR (1) AR048527A1 (es)
AU (1) AU2005233133A1 (es)
BR (1) BRPI0509191A (es)
CA (1) CA2561010A1 (es)
CR (1) CR8615A (es)
EC (1) ECSP066911A (es)
IL (1) IL178236A0 (es)
NO (1) NO20065052L (es)
PA (1) PA8629101A1 (es)
PE (1) PE20060676A1 (es)
RU (1) RU2006132180A (es)
SG (1) SG151331A1 (es)
TW (1) TWI346105B (es)
WO (1) WO2005100316A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005233133A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
JP2007532548A (ja) * 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
US10645562B2 (en) 2004-09-21 2020-05-05 Agis Software Development Llc Method to provide ad hoc and password protected digital and voice networks
US8538393B1 (en) 2004-09-21 2013-09-17 Advanced Ground Information Systems, Inc. Method to provide ad hoc and password protected digital and voice networks
WO2007002823A2 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
TW200738281A (en) * 2005-08-24 2007-10-16 Wyeth Corp Bazedoxifene acetate formulations
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
ES2436662T3 (es) 2008-02-11 2014-01-03 Wyeth Llc Procedimientos de preparación de la forma polimórfica A de acetato de bazedoxifeno
WO2009102778A1 (en) * 2008-02-11 2009-08-20 Wyeth Amorphous polymorph of bazedoxifene acetate
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
AR078785A1 (es) 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
US8154175B2 (en) * 2009-12-16 2012-04-10 Hamilton Sundstrand Corporation Sensing device
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012037187A2 (en) * 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
US9751835B2 (en) 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN111060619B (zh) * 2019-12-18 2022-11-18 北京鑫开元医药科技有限公司 一种醋酸巴多昔芬杂质的检测方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
ATE206701T1 (de) 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ATE355264T1 (de) 1997-10-15 2006-03-15 Wyeth Corp Neue aryloxy-alkyl-dialkylamine
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
AU2005233133A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate

Also Published As

Publication number Publication date
US7683051B2 (en) 2010-03-23
JP2009035535A (ja) 2009-02-19
NO20065052L (no) 2006-11-06
IL178236A0 (en) 2006-12-31
CA2561010A1 (en) 2005-10-27
KR20060135866A (ko) 2006-12-29
JP2007532560A (ja) 2007-11-15
PE20060676A1 (es) 2006-07-24
ECSP066911A (es) 2006-12-20
AR048527A1 (es) 2006-05-03
TWI346105B (en) 2011-08-01
RU2006132180A (ru) 2008-05-20
EP1732890A1 (en) 2006-12-20
WO2005100316A1 (en) 2005-10-27
SG151331A1 (en) 2009-04-30
PA8629101A1 (es) 2005-11-25
AU2005233133A1 (en) 2005-10-27
BRPI0509191A (pt) 2007-09-25
US20050227965A1 (en) 2005-10-13
TW200606149A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CR8615A (es) Polimorfo cristalino de un acetato de bazedoxifeno
CR9746A (es) Bazedoxifene acetate formulations
ECSP066910A (es) Polimorfo cristalino de acetato de bazedoxifeno
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CR9014A (es) Novedosos derivados de heteroarilsulfamida benzofusionados como agentes anticonvulsionantes
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
BRPI0411528A (pt) uso de isomalte como prebiótico
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
CR9930A (es) Compuestos
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200900082A (es) Composiciones de fenilalquilamino-carbamato
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
CR8617A (es) Formulaciones de dispersiones solidas de acetato de bazedoxifeno
SG158091A1 (en) Imidazoazepinone compounds
BR0311609A (pt) composições de fórmula infantil contendo luteìna e zeaxantina
UY30788A1 (es) Compuestos quimicos
CR8616A (es) Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
CR8614A (es) Polimorfo cristalino de acetato de bazedoxifeno
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
CR9578A (es) Inhibidores de la adenilato ciclasa soluble
SV2006002079A (es) Polimorfo cristalino de acetato de bazedoxifeno ref. wyth0049-504 (am101381)
CR9435A (es) Uso de un compuesto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)